-
Information
iCFO Information Booth How can we help? -
Investor
Nex Cubed Nex Cubed is a global accelerator that invests in diverse founders that are solving problems that matter.
-
Investor
Thomas Duffy
-
Investor
Andrew Thompson
-
Investor
Greenroom Ventures
-
Investor
Len Brandt
-
Investor
Robert Medralla
-
Investor
Ara Kachadourian
-
Investor
GRIFFITH INVESTMENTS
-
Investor
Don Koller
-
Investor
William Feaster
-
Investor
Cogent Growth Capital High Yield, Low Risk Sustainable ESG Impact Investments
-
Investor
Sanderling Ventures Dedicated to early-stage biomedical financing and active management
-
Investor
Sai Gonuguntla
-
Investor
Paul Stein
-
Investor
Corporate Capital Advisor
-
Investor
Verano Capital Partners
-
Investor
Raymond Zoeller Zoeller Associates
-
Investor
Enascor Capital
-
Investor
Dr. Sam Arafeh Angel Investor
-
Entrepreneur
Redkik Modernizing the Acquisition of Insurance
-
Entrepreneur
Akelos Inc.
-
Entrepreneur
Orion Innovations Where Smart Meets Simple
-
Entrepreneur
Nicholas Pharmaceuticals, LLC
-
Entrepreneur
iinventt THE ONE-STOP SHOP TO DEVELOP YOUR PRODUCTS
-
Entrepreneur
The Plexer Group
-
Entrepreneur
Waterfall Music
-
Entrepreneur
Zen Health Technologies AI-powered, virtual reality training to improve workplace culture
-
Entrepreneur
BOKO Therapeutics
-
Entrepreneur
Cricadiance Remote Patient Monitoring
Event Live Web Event: The iCFO Capital Global Virtual Investor Conference - Scottsdale, AZ is over.
Join us next time to meet Kevin Sill!
Join us next time to meet Kevin Sill!
About Welton Pharma
Welton Pharma
Welton is utilizing Apisolex drug delivery technology to optimize pharmaceutical drug products
Available from
12:00 PM
-
4:00 PM
(US/Pacific)
+1 813-892-9520
Welton Pharma was founded to develop pharmaceutical drug products. The company has in-licensed Lubrizol's Apisolex technology, invented by Welton Co-founders, to solubilize drugs that are not otherwise soluble in water. Welton will utilize this technology to provide novel, patent protected formulations that offer meaningful improvements to marketed drug products. Their lead product is anticipated to increase the response rate in cancer patients by 300% when compared to current standard of care.
